Total dose infusion of intravenous iron in patients with chronic kidney disease receiving haemodialysis.

A regimen of a single high dose iron administration was initially adopted for patients commencing haemodialysis (HD) treatment. Iron stores are established and iron metabolism and erythropoiesis stabilise allowing haematinic parameters to be more confidently assessed for use in anaemia management decisions. High doses of IV iron delay the need for subsequent iron supplementation.

Comparison of intravenous iron sucrose versus low-molecular-weight iron dextran in chronic kidney disease.

Background: Low-molecular-weight iron dextran (CosmoFer) is the only form of parenteral iron that can be administered as a total dose infusion (TDI) in the United Kingdom (UK). This study aimed to evaluate the safety and efficacy of TDI CosmoFer in comparison to intravenous iron sucrose infusion (Venofer) in patients with chronic kidney disease (CKD).

Methods And Results: A retrospective study of outpatients with CKD undergoing intravenous TDI CosmoFer or Venofer infusion was conducted at Salford Royal Hospital and Sunderland Royal Hospital.

Intravenous iron administration in a short-stay hospital setting.

Anaemia and iron deficiency are prevalent in the Western and developing world. They have implications for quality of life, prognosis and survival in a number of clinical settings. These range from the implications of anaemic status and associated outcomes in pregnancy, reduced blood transfusion requirements following surgery to lethargy and tiredness in older people if left unrecognised and untreated.

Clinical management. Where medicine meets management. Pumping iron.

Non-haemodialysis renal patients requiring intravenous iron therapy are increasing the pressure on renal units. A new form of iron therapy can dramatically reduce patient visits, but takes longer to administer. Sunday provision of nurse-led clinics has enabled a switch to this new therapy.